Prostate cancer is dependent on androgens. This disease will not develop if androgens are eliminated from the body at a young age (as with castration), and abatement of androgenic activity in patients with active disease is regarded as a standard path of treatment. A complete picture of the involvement of androgens, however, remains unclear. Studies show there is no association between the testosterone level and likelihood of developing prostate cancer. On the same note, the administration of exogenous testosterone during androgen replacement therapy seems to have no effect on the risk for developing this disease. A review of the available medical literature also does not support an increased risk of prostate cancer in steroid abusers, which typically endure excessive levels of androgenic stimulation. The present model suggests that while testosterone is a necessary component of prostate cancer, it does not appear to be a direct trigger for its onset.
New diagnoses of prostate cancer are sometimes reported during testosterone replacement therapy and steroid abuse. Such reports may be the result of a previously undiagnosed condition or unrelated development of this disease, with androgen stimulation assisting the tumor growth rate. Many forms of prostate cancer possess functional androgen receptors, and are highly androgen responsive. As such, they can be stimulated to grow under the influence of testosterone or other anabolic/androgenic steroids. Given this effect, AAS drugs are usually contraindicated in patients with a history of prostate cancer. While steroid administration appears unlikely to cause prostate cancer, individuals remain warned that the use of testosterone or other AAS drugs by someone with previously undiagnosed (latent) malignant prostate cancer could result in the more rapid advancement of this disease.
Wlliam Llewellyn (2011) - Anabolics